Hyloris Pharmaceuticals SA announced that Jean-Luc Vandebroek will be joining the company as its Chief Financial Officer. In addition to his new role at Hyloris, Jean-Luc will remain Non-Executive Director of the Board of Bone Therapeutics during a transition period to lead a managed succession. Jean-Luc will report to Hyloris’ CEO, and previously acting interim CFO, Stijn Van Rompay. Jean-Luc Vandebroek is a seasoned executive who most recently served as CFO of Bone Therapeutics, a publicly traded biotech company based in Gosselies, Belgium. Prior to that, he was CFO and CIO at Alcopa and Fluxys, and before that, he held various senior financial positions at Delhaize Group. Jean-Luc is an experienced Executive Board member and has a track record of developing and implementing financing strategies and transactions and has a large, global network of investors and financial institutions.